Efficacy and adverse effects of immune checkpoint inhibitor for advanced epidermal growth factor receptor tyrosine kinase-resistant non-small cell lung cancer / 中国肿瘤临床

ABSTRACT

Objective: To investigate the efficacy and adverse effects of immune checkpoint inhibitor (ICI) for advanced non-small cell lung cancer (NSCLC) resistant to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Methods: The clinical data of 49 patients with advanced NSCLC who received ICI treatment after EGFR-TKI resistance in the Chinese People's Liberation Army General Hospital from January 2015 to March 2019 were collected. Statistical methods were used to analyze the efficacy and adverse effects of immunotherapy in patients with EGFR TKI-resistant NSCLC, and to clarify the relationship between clinical characteristics and the curative efficacy and prognosis of patients. Results: The objective response rate was significantly higher in patients with combination therapy than those with monotherapy (28.6% vs. 7.1%, P60 years had longer progression free survival than those with moderate differentiation (5.1 vs. 2.8 months, P=0.03), monotherapy (6.8 vs. 2.3 months, P60 years and combination therapy were independent protective factors for PFS (P<0.001). Although combination therapy group had higher overall adverse event rate than monotherapy group, there was no significant difference in the adverse reaction rate of grade 3 and above between both groups (P= 0.28). Conclusions:The efficacy of monotherapy with ICI was poor in EGFR TKI-resistant patients with late-stage NSCLC, while combination therapy could significantly improve the curative efficacy and prognosis of patients. Although the overall rate of adverse events